Analyst consensus rating
BioCryst Pharmaceuticals Analyst Rating: Strong Buy
BCRX is rated Strong Buy by 11 analysts with a $20.82 target. As of 2026-08-26.
Direct answer
BioCryst Pharmaceuticals's consensus rating is Strong Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $20.82.
Forecast evidence checked August 26, 2026.
Get free BioCryst Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $9.83
- Average price target
- $20.82
- High price target
- $32.00
- Low price target
- $12.00
- Low target gap
- +22.1%
- Target upside
- +111.8%
- High target gap
- +225.5%
- Target range width
- 203.5%
- Consensus rating
- Strong Buy
- Analysts
- 11
- Evidence date
- August 26, 2026
- Valid through
- September 2, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $20.82.
How far are BioCryst Pharmaceuticals's low and high targets from the recorded price?
The low target implies +22.1%, while the high target implies +225.5%.
How many analysts are included in BioCryst Pharmaceuticals's consensus?
The verified consensus includes 11 analysts.
How is BioCryst Pharmaceuticals's target upside or downside calculated?
The average target of $20.82 is divided by the recorded price of $9.83, then one is subtracted to produce +111.8%. This does not guarantee a future return.
When was BioCryst Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-26. The dataset is valid through 2026-09-02.